Search research articles
Contact Us
Filters
Showing results (101-110 of 175) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
Howard I Scher, Xiaoyu Jia, Kim Chi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 26, 2009
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy
Alexandra W van den Belt-Dusebout, Berthe M P Aleman, Gijs Besseling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2017
Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
Bodine P S Belderbos, Sander Bins, Roelof W F van Leeuwen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2019
Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer
Bodine P S Belderbos, Anieta M Sieuwerts, Esther Oomen-de Hoop, et al.
The Lancet. Oncology
|
February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad, Karim Fizazi, Viorel Jinga, et al.
The New England Journal of Medicine
|
October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 5, 2016
Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study
Tom J N Hermans, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Molecular Oncology
|
May 13, 2023
mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer
Khrystany T Isebia, Bianca Mostert, Teoman Deger, et al.
Cancer Immunology, Immunotherapy : CII
|
August 17, 2022
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Maud Rijnders, Debbie G J Robbrecht, Astrid A M Oostvogels, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 175) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
Howard I Scher, Xiaoyu Jia, Kim Chi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 26, 2009
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy
Alexandra W van den Belt-Dusebout, Berthe M P Aleman, Gijs Besseling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2017
Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
Bodine P S Belderbos, Sander Bins, Roelof W F van Leeuwen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2019
Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer
Bodine P S Belderbos, Anieta M Sieuwerts, Esther Oomen-de Hoop, et al.
The Lancet. Oncology
|
February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad, Karim Fizazi, Viorel Jinga, et al.
The New England Journal of Medicine
|
October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 5, 2016
Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study
Tom J N Hermans, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Molecular Oncology
|
May 13, 2023
mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer
Khrystany T Isebia, Bianca Mostert, Teoman Deger, et al.
Cancer Immunology, Immunotherapy : CII
|
August 17, 2022
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Maud Rijnders, Debbie G J Robbrecht, Astrid A M Oostvogels, et al.
Page
of 18